STI ¹× Áú¿° PCR °Ë»ç ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Çâ, »ê¾÷ ºÐ¼® º¸°í¼­ : º´Åº°(¼º°¨¿°Áõ, Áú¿°), °Ë»ç À¯Çüº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº° - ½ÃÀå ¿¹Ãø(2025-2034³â)
STI and Vaginitis PCR Testing Market Size, Share, Trends, & Industry Analysis Report By Condition [Sexually Transmitted Infections (STIs) and Vaginal Infections], By Test Type, By End Use, and By Region - Market Forecast, 2025-2034
»óǰÄÚµå : 1766395
¸®¼­Ä¡»ç : Polaris Market Research
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 125 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,250 £Ü 5,953,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,250 £Ü 7,354,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ 20¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,250 £Ü 8,755,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Polaris Market ResearchÀÇ ÃֽŠÁ¶»ç¿¡ µû¸£¸é, ¼¼°è STI ¹× Áú¿° PCR °Ë»ç ½ÃÀå ±Ô¸ð´Â 2034³â±îÁö 15¾ï 7,843¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ º¸°í¼­´Â ÇöÀç ½ÃÀå ¿ªÇп¡ ´ëÇÑ ÀÚ¼¼ÇÑ ÀλçÀÌÆ®¿Í ÇâÈÄ ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

STI ¹× Áú¿° PCR °Ë»ç ½ÃÀåÀº STI ¹× ´Ù¾çÇÑ À¯ÇüÀÇ Áú °¨¿°¿¡ ´ëÇÑ º´¿øÃ¼ ƯÀÌÀû °Ë»ç¸¦ À§ÇØ ÁßÇÕÈ¿¼Ò ¿¬¼â ¹ÝÀÀ(PCR) ±â¼úÀ» ÀÌ¿ëÇÑ °í±Þ Áø´ÜÀ» ¼öÇàÇÏ´Â µ¥ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù. PCR °Ë»ç´Â ³ôÀº ¹Î°¨µµ¿Í ƯÀ̼º, ±×¸®°í ¾Æ¹«¸® ¹Ì·®ÀÌ¶óµµ ¿øÀαÕÀÇ À¯Àü¹°ÁúÀ» Á¤È®ÇÏ°Ô Æ÷ÂøÇÏ´Â ´É·ÂÀ¸·Î ´Ù¸¥ °Ë»ç¹ý¿¡¼­´Â ã¾Æº¼ ¼ö ¾ø´Â µ¶Æ¯ÇÑ °Ë»ç¹ýÀÔ´Ï´Ù. ´Ù¸¥ °Ë»ç¹ý¿¡´Â ¾ø´Â µ¶Æ¯ÇÑ °ÍÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Á¤È®¼ºÀº ½Å¼ÓÇϰí Á¤È®ÇÑ Áø´Ü°ú Áúº´ÀÇ ÁøÇà ¹× Ãß°¡ °¨¿°ÀÇ Çʿ伺¿¡ ´ëóÇϱâ À§ÇÑ °­·ÂÇϰí Á¤È®ÇÑ Ä¡·á °èȹÀ» ¼ö¸³ÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù.

ÀÌ ºÐ¾ßÀÇ °Ë»ç¿¡ ´ëÇÑ ±â´ë´Â ¿©·¯ °¡Áö ÀÌÀ¯·Î ƯÈ÷ ³«°üÀûÀÔ´Ï´Ù. Áö¿ªÀûÀ¸·Î STI¿Í Áú¿°ÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Á¤È®ÇÑ Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¸ÖƼÇ÷º½º PCR ºÐ¼®¹ý °³¹ß°ú °°Àº ºÐÀÚÁø´Ü µµ±¸ÀÇ °³¹ßµµ ÀÌ ºÐ¾ßÀÇ ¼ºÀåÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ´ÜÀÏ »ùÇÿ¡¼­ ¿©·¯ º´¿øÃ¼¸¦ °ËÃâÇÒ ¼ö ÀÖ´Â ´É·ÂÀº È¿À²¼ºÀ» ³ôÀ̰í ÀÓ»óÀÇ¿¡°Ô Áø´Ü Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, ´ëÁßÀÇ Àνİú Àû±ØÀûÀÎ °ËÁø Ä·ÆäÀÎÀº Áý´Ü °ËÁøÀÇ °­µµ¸¦ ³ôÀ̰í ÀÖÀ¸¸ç, ÀÌ´Â ¸íÈ®ÇÏ°Ô Á¤ÀÇµÈ ¼º ¹× »ý½Ä °Ç°­À» ÇâÇÑ °í¹«ÀûÀÎ Ãß¼¼ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ º¯È­¿¡´Â Á¤È®ÇÏ°í ½Å·ÚÇÒ ¼ö ÀÖ´Â Áø´Ü µµ±¸°¡ ÇÊ¿äÇϸç, À̸¦ ÅëÇØ ¸ñÀûÀǽÄÀ» °¡Áö°í Àü·«ÀûÀ¸·Î ¹®ÀÚ¿¡ Á¢±ÙÇÒ ¼ö ÀÖµµ·Ï ÇØ¾ß ÇÕ´Ï´Ù.

STI ¹× Áú¿° PCR °Ë»ç ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

Áúȯº°·Î´Â ¼ºº´(STI) ºÐ¾ß°¡ 2024³â °¡Àå Å« ºñÁßÀ» Â÷ÁöÇß½À´Ï´Ù. ÀÌ´Â ´Ù¾çÇÑ STIÀÇ Àü ¼¼°è À¯º´·üÀÌ Áö¼ÓÀûÀ¸·Î ³ô°í, ´ëºÎºÐ ¹«Áõ»óÀ̸ç, ±¤¹üÀ§ÇÑ ½ºÅ©¸®´× ¹× °øÁß º¸°Ç °ü¸®¸¦ À§ÇØ PCR°ú °°Àº Á¤È®ÇÏ°í ¹Î°¨ÇÑ Áø´Ü µµ±¸°¡ ¸Å¿ì Áß¿äÇϱ⠶§¹®ÀÔ´Ï´Ù.

°Ë»ç À¯Çüº°·Î´Â STI PCR ÆÐ³Î ºÎ¹®ÀÌ 2024³â ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ù. ÀÌ·¯ÇÑ ¿ìÀ§´Â ÁÖ·Î Á¾ÇÕÀûÀÎ Áø´Ü ¹× Ä¡·á Áöħ¿¡ ÇʼöÀûÀÎ ¸ÖƼÇ÷º½º ÆÐ³ÎÀ» ÅëÇÑ ±¤¹üÀ§ÇÑ ¼ºº´ º´¿øÃ¼ÀÇ Á¤È®ÇÏ°í ¹Î°¨ÇÑ µ¿½Ã °ËÃâ¿¡ ´ëÇÑ Áß¿äÇÑ ¿ä±¸»çÇ׿¡ ±âÀÎÇÕ´Ï´Ù.

ÃÖÁ¾ ¿ëµµº°·Î´Â Áø´Ü ½ÇÇè½Ç ºÎ¹®ÀÌ 2024³â °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ´Â Àü¹® ÀÎÇÁ¶ó, ³ôÀº 󸮷®, ´Ù¾çÇÑ ÀÇ·á ȯ°æ¿¡¼­ ´ë·®ÀÇ º¹ÀâÇÑ ºÐÀÚÁø´Ü Å×½ºÆ®¸¦ ó¸®ÇÏ´Â µ¥ ÇÊ¿äÇÑ Àü¹® Áö½ÄÀÌ ÇÊ¿äÇϱ⠶§¹®ÀÔ´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ STI ¹× Áú¿° PCR °Ë»ç ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ÀÌ´Â ÁַΠźźÇÑ ÀÇ·á ÀÎÇÁ¶ó, ¼º °Ç°­¿¡ ´ëÇÑ ³ôÀº ÀνÄ, PCR ±â¹Ý ºÐ¼®À» Æ÷ÇÔÇÑ Ã·´Ü Áø´Ü ±â¼úÀÇ Á¶±â µµÀÔ¿¡ ±âÀÎÇÕ´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ STI ¹× Áú¿° PCR °Ë»ç ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È »ó´çÇÑ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀº ÀÇ·á ÀÎÇÁ¶ó °³¼±, °¡Ã³ºÐ ¼Òµæ Áõ°¡, Áß±¹ ¹× Àεµ¿Í °°Àº ±¹°¡¿¡¼­ ¼º ¹× »ý½Ä °Ç°­¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁ³±â ¶§¹®ÀÔ´Ï´Ù.

ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À¸·Î´Â Hologic, Inc., BD (Becton, Dickinson and Company), bioMerieux, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Qiagen, OraSure Technologies, and SpeeDx Pty Ltd. µîÀÌ ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Cepheid (Danaher) and Luminex Corporation (DiaSorin S.p.A.)°ú °°ÀÌ ´õ Å« ¸ðȸ»ç »êÇÏ¿¡ ¿î¿µµÇ´Â ÁÖ¿ä ±â¾÷µµ ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼Ò°³

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ¼¼°èÀÇ STI ¹× Áú¿° PCR °Ë»ç ½ÃÀå ÀλçÀÌÆ®

Á¦5Àå ¼¼°èÀÇ STI ¹× Áú¿° PCR °Ë»ç ½ÃÀå : º´Åº°

Á¦6Àå ¼¼°èÀÇ STI ¹× Áú¿° PCR °Ë»ç ½ÃÀå : °Ë»ç À¯Çüº°

Á¦7Àå ¼¼°èÀÇ STI ¹× Áú¿° PCR °Ë»ç ½ÃÀå : ÃÖÁ¾ ¿ëµµº°

Á¦8Àå ¼¼°èÀÇ STI ¹× Áú¿° PCR °Ë»ç ½ÃÀå : Áö¿ªº°

Á¦9Àå °æÀï ±¸µµ

Á¦10Àå ±â¾÷ °³¿ä

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global STI and vaginitis PCR testing market size is expected to reach USD 1,578.43 million by 2034, according to a new study by Polaris Market Research. The report "STI and Vaginitis PCR Testing Size, Share, Trends & Industry Analysis Report: By Condition [Sexually Transmitted Infections (STIs) and Vaginal Infections], By Test Type, By End Use, and By Region - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The STI and vaginitis PCR testing market focuses on the implementation of advanced diagnostics using polymerase chain reaction (PCR) technology for pathogen specific testing of STIs and different types of vaginal infections. These infections encompass common sexually transmitted infections (STIs) such as chlamydia, gonorrhea, and trichomoniasis, alongside vaginal infections such as bacterial vaginosis and vulvovaginal candidiasis. PCR testing is unique among other testing methods due to its high sensitivity and specificity, and its ability to accurately capture the genetic material of causative organisms, no matter how minute the quantities are. This level of precision is essential for prompt and accurate diagnosis and an intense and precise treatment plan that addresses disease progression and further transmission needs.

The expectations related to this area of testing are particularly optimistic for multiple reasons. The rising prevalence of STIs and vaginitis regionally augments the demand for accurate diagnosis. The advancement in molecular diagnostic tools, as in the case of multiplex PCR assay development, is also accelerating growth in this area. The ability to detect multiple pathogens from a single sample increases both efficiency and provides enhanced diagnostic information for clinicians. Moreover, public awareness and proactive screening campaigns heighten population testing intensity, which is an encouraging trend directed toward explicitly defined sexual and reproductive health. Such changes necessitate accurate and reliable tools for diagnosis and, thereby, purposeful and strategic toward letter accessibility.

STI and Vaginitis PCR Testing Market Report Highlights:

By condition, the sexually transmitted infections (STIs) segment held a larger share in 2024, driven by the persistent high global prevalence of various STIs, many of which are asymptomatic, and the crucial need for accurate, sensitive diagnostic tools such as PCR for widespread screening and public health management.

By test type, the STI PCR panels segment dominated the market in 2024. The dominance is primarily attributed to the critical requirement for accurate and sensitive detection of a broad range of sexually transmitted pathogens, often simultaneously through multiplex panels, which are essential for comprehensive diagnosis and treatment guidance.

By end use, the diagnostic laboratories segment held the largest share in 2024, owing to their specialized infrastructure, high-throughput capabilities, and the expertise necessary for processing a large volume of complex molecular diagnostic tests from various healthcare settings.

By region, North America holds a substantial share of the STI and vaginitis PCR testing market. This is largely attributed to the robust healthcare infrastructure, high awareness regarding sexual health, and the early adoption of advanced diagnostic technologies, including PCR-based assays. The Asia Pacific STI and vaginitis PCR testing market is anticipated to exhibit a significant growth rate during the forecast period. This growth is primarily fueled by improving healthcare infrastructure, increasing disposable incomes, and a rising awareness about sexual and reproductive health in countries such as China and India.

A few key players in the market include Hologic, Inc.; BD (Becton, Dickinson and Company); bioMerieux; F. Hoffmann-La Roche Ltd; Thermo Fisher Scientific Inc.; Abbott Laboratories; Qiagen; OraSure Technologies; and SpeeDx Pty Ltd. Additionally, some key entities operate under larger parent organizations, such as Cepheid (Danaher) and Luminex Corporation (DiaSorin S.p.A.).

Polaris Market Research has segmented the STI and vaginitis PCR testing market report on the basis of condition, test type, end use, and region:

By Condition Outlook (Revenue - USD Million, 2020-2034)

Sexually Transmitted Infections (STIs)

Chlamydia

Gonorrhea

Trichomoniasis

Herpes Simplex Virus (HSV-1 & HSV-2)

Human Papillomavirus (HPV)

Syphilis

Other

Vaginal Infections

Bacterial Vaginosis

Vulvovaginal Candidiasis

Other

By Test Type Outlook (Revenue - USD Million, 2020-2034)

STI PCR Panels

Vaginitis PCR Panels

By End Use Outlook (Revenue - USD Million, 2020-2034)

Hospitals & Clinics

Diagnostic Laboratories

Homecare/At-home Testing

Others

By Regional Outlook (Revenue - USD Million, 2020-2034)

North America

US

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America

Table of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Global STI and Vaginitis PCR Testing Market Insights

5. Global STI and Vaginitis PCR Testing Market, by Condition

6. Global STI and Vaginitis PCR Testing Market, by Test Type

7. Global STI and Vaginitis PCR Testing Market, by End Use

8. Global STI and Vaginitis PCR Testing Market, by Geography

9. Competitive Landscape

10. Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â